Gleason 7 Prostate Cancer: What Should You Do?
Gleason 7 prostate cancer is often described as “intermediate-risk” disease, but this can be misleading. Some men with Gleason 3+4=7 cancer may be suitable for active surveillance, while others have disease that behaves more aggressively and is best treated early. Understanding the biology of your cancer is often more important than the Gleason score alone.
to discuss your diagnosis and treatment options.
What does Gleason 7 mean?
Gleason 7 prostate cancer is considered intermediate-risk disease, but it is not a single entity.
It includes two different patterns:
- Gleason 3+4 (Grade Group 2) → generally less aggressive
- Gleason 4+3 (Grade Group 3) → more aggressive
This distinction is critical in determining treatment.
Do you need treatment?
- Gleason 7 prostate cancer can be categorised as either favourable intermediate-risk prostate cancer (3+4=7, or ISUP Grade Group 2 prostate cancer) or unfavourable intermediate-risk prostate cancer (4+3=7, or ISUP Grade Group 3 prostate cancer)
- The key distinction between the two groups is the proportion of Gleason pattern 4 disease present within the tumour
- When Gleason pattern 4 becomes the predominant pattern of disease, the risk of progression and metastatic spread increases
- As a general rule, some patients with favourable intermediate-risk disease may be suitable for active surveillance, whereas most patients with unfavourable intermediate-risk prostate cancer will require definitive treatment
Clinical scenarios in Gleason 7 prostate cancer
The following examples demonstrate how age, MRI findings, tumour volume, Gleason pattern 4 and overall health influence treatment recommendations.
Scenario 1: Active surveillance for favourable intermediate-risk disease
A 64 year old man has a PSA of 8.2 ng/mL, which remains stable on repeat testing. MRI demonstrates a small equivocal lesion (PI-RADS 3), and biopsy shows a single focus of ISUP Grade Group 2 (Gleason 3+4=7) prostate cancer with 5% Gleason pattern 4 disease.
Although suitable for definitive treatment with surgery or radiation therapy, this patient has low volume, favourable intermediate-risk prostate cancer that is suitable for active surveillance. Because the proportion of Gleason pattern 4 disease is low (5%) and there is no clearly suspicious lesion on MRI, the risk of progression in the short to medium term is low.
Scenario 2: Surgery or radiotherapy
A 54 year old man with a strong family history of prostate cancer has a PSA that has risen from 1.8 ng/mL to 3.3 ng/mL over a short period. MRI demonstrates a PI-RADS 4 lesion, and biopsy confirms ISUP Grade Group 2 (Gleason 3+4=7) prostate cancer within the MRI visible lesion.
Although active surveillance remains an option, this patient’s age, family history and MRI-visible disease suggest a higher risk of progression. Definitive treatment should therefore be strongly considered. For a man of 54 years with a life expectancy of approximately 30 years, surgery would often be favoured because it provides definitive pathological staging and avoids the potential long-term urinary, bowel and secondary malignancy risks associated with radiotherapy.
Scenario 3: Active surveillance for unfavourable intermediate-risk disease
A 72 year old man with a past medical history that includes a prior heart attack, hypertension, high cholesterol and diabetes and no family history of prostate cancer has a PSA of 9.2 ng/mL and 9.0 ng/mL on repeat testing. MRI demonstrates no suspicious lesions. However, because he has a small prostate, his PSA density is elevated. He undergoes a biopsy, which reveals 3mm of Grade Group 3 (Gleason 4+3=7) prostate cancer.
Treatment is often recommended for patients with unfavourable intermediate-risk prostate cancer. However, given the patient’s age, medical comorbidities, negative MRI and very low volume of disease, the potential benefits of treatment are less clear and active surveillance is a reasonable management strategy.
Is Gleason 7 prostate cancer serious?
It is considered intermediate-risk. Some cases behave more like low-risk disease, while others are more aggressive.
Can Gleason 7 be cured?
Yes. Many patients with Gleason 7 prostate cancer achieve long-term cancer control with appropriate treatment.
Is Gleason 7 always treated?
No. Some patients, particularly with Gleason 3+4=7 disease, may be managed with active surveillance.
Should I get a second opinion?
Yes. Gleason 7 is a nuanced diagnosis, and a second opinion can help clarify the best approach.
Book a consultation
If you have been diagnosed with Gleason 7 prostate cancer, a consultation can help clarify your options and determine the most appropriate treatment approach.
